title: Factors potentially associated with chemotherapy-induced anemia in patients with solid cancers.
abstract: OBJECTIVE
  Chemotherapy-induced anemia (CIA) is one of the most important causes of anemia in cancer patients. This study was conducted to describe the prevalence and characteristics of CIA in solid cancer patients in the Chinese population, and to explore the relationship of white blood cell (WBC) or platelet decrease with CIA.
  
  
  METHODS
  Data on age, gender, tumor diagnosis, anti-cancer treatment and blood cell analyses were available from 220 untreated non-anemic cancer patients who received at least 2 cycles of chemotherapy, and the data were analyzed to assess their relationship with CIA or its severity.
  
  
  RESULTS
  139 patients (63.2%) presented anemia, most being Grade 1 or 2. Esophageal and lung cancers were associated with a high prevalence. G3/4 leucopenia and decrease of platelets were identified as independent risk factors for the occurrence of CIA. Moreover, G3/4 leucopenia, decrease of platelet and G3/4 thrombocytopenia were found to be also associated with the severity of CIA. Cisplatin-containing regimens were a main potential factor in causing CIA, although significant association was only found on univariate analysis.
  
  
  CONCLUSIONS
  Anemia or decrease in hemoglobin are common in Chinese cancer patients receiving chemotherapy. Cisplatin-containing regimens might be an important factor influencing the occurrence of CIA. Our analysis firstly described some risk factors, such as decrease of platelets or WBCs, severity of leucopenia or thrombocytopenia, associated with the occurrence and severity of CIA.
authors.affiliation: Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Cheng
authors.forename: Feng
authors.initials: F
authors.lastname: Zhao
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Hang
authors.initials: H
authors.lastname: Dong
authors.forename: Hai-Tao
authors.initials: HT
authors.lastname: Men
authors.forename: Ye
authors.initials: Y
authors.lastname: Chen
authors.forename: Long-Hao
authors.initials: LH
authors.lastname: Li
authors.forename: Jun
authors.initials: J
authors.lastname: Ge
authors.forename: Jie
authors.initials: J
authors.lastname: Tang
authors.forename: Jing
authors.initials: J
authors.lastname: Ding
authors.forename: Xin
authors.initials: X
authors.lastname: Chen
authors.forename: Yang
authors.initials: Y
authors.lastname: Du
authors.forename: Wu-Xia
authors.initials: WX
authors.lastname: Luo
authors.forename: Ji-Yan
authors.initials: JY
authors.lastname: Liu
mesh_terms: D000740:Anemia / Q000139:chemically induced / Q000175:diagnosis / Q000453:epidemiology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D011379:Prognosis; D012307:Risk Factors